ReviewGene therapy2003
Gene- and cell-based therapeutics for type I diabetes mellitus.
Review in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Rheb1 signaling and the fate of pancreatic β cells: Toward a new frontier in diabetes therapy.World journal of diabetes · 2025Article
- Regulated hAAT Expression from a Novel rAAV Vector and Its Application in the Prevention of Type 1 Diabetes.Journal of clinical medicine · 2019Article
- The Association between Depression and Type 1 Diabetes Mellitus: Inflammatory Cytokines as Ferrymen in between?Mediators of inflammation · 2019Review
- The combined effect ofFEBS open bio · 2018Article
- Nucleotide sequencing, cloning, and expression of Capra hircus Heme Oxygenase-1 in caprine islets to promote insulin secretion in vitro.Molecular biotechnology · 2015Article
- Efficient down-regulation of glia maturation factor expression in mouse brain and spinal cord.Neurochemical research · 2012Article
- Genetically engineered islets and alternative sources of insulin-producing cells for treating autoimmune diabetes: quo vadis?International journal of endocrinology · 2012Article
- Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.Immunologic research · 2011Article
- Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Clinical & developmental immunology · 2011Review
- Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury.Human gene therapy · 2009Article
- Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice.Journal of biomedical science · 2009Article
- Autologous umbilical cord blood infusion for type 1 diabetes.Experimental hematology · 2008Review
- Polymeric gene transfection on insulin-secreting cells: sulfonylurea receptor-mediation and transfection medium effect.Pharmaceutical research · 2006Article
- Gene therapy for type 1 diabetes: is it ready for the clinic?Immunologic research · 2006Review
- Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors.Gene therapy · 2005Article
- Gene therapy progress and prospects: gene therapy for diabetes mellitus.Gene therapy · 2005Review
- Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus, an autoimmune disorder is an attractive candidate for gene and cell-based therapy. From the use of gene-engineered immune cells to induce hyporesponsiveness to autoantigens to islet and beta cell surrogate transplants expressing immunoregulatory genes to provide a local pocket of immune privilege, these strategies have demonstrated proof of concept to the point where translational studies can be initiated. Nonetheless, along with the proof of concept, a number of important issues have been raised by the choice of vector and expression system as well as the point of intervention; prophylactic or therapeutic. An assessment of the current state of the science and potential leads to the conclusion that some strategies are ready for safety trials while others require varying degrees of technical and conceptual refinement.
Indexed as
Identifiers
12732873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.